Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

AbbVie Surges 6% in Three Days, $15.76 Billion Trading Volume Lands 39th in Market Activity

Market BriefThursday, Apr 24, 2025 7:45 pm ET

1min read

AbbVie (ABBV) rose 1.88% on April 24, 2025, marking its third consecutive day of gains, with a total increase of 6.00% over the past three days. The company's trading volume reached $15.76 billion, placing it 39th in the day's market activity.

AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for TrenibotulinumtoxinE (TrenibotE), a treatment designed to reduce the appearance of frown lines. This submission is a significant step for AbbVie as it seeks to expand its portfolio in the facial aesthetics market. The approval of TrenibotE could provide patients with an additional option for managing glabellar lines, potentially enhancing AbbVie's offerings in the aesthetics sector. The FDA's decision on this application will be crucial in determining the availability of this novel therapy to healthcare providers and patients seeking alternatives in cosmetic treatments.

In its recent financial report, AbbVie delivered full-year adjusted earnings per share of $10.12, surpassing initial guidance by $0.49. Total net revenues reached $56.3 billion, exceeding initial guidance by more than $2 billion. The ex-HUMIRA platform showed strong performance with a 22% revenue growth in the fourth quarter. SKYRIZI and RINVOQ combined revenue was approximately $17.7 billion, an increase of nearly $6 billion year over year. The neuroscience segment is projected to achieve $10 billion in sales in 2025, reflecting growth across psychiatry, migraine, and Parkinson's treatments. However, global sales of HUMIRA declined by 48.7% due to biosimilar competition, and the aesthetics segment experienced a 4.4% operational decrease in sales, impacted by challenging market conditions in the US and China.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.